We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
-8.44%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$139M
AUM Growth
-$143M
Cap. Flow
-$114M
Cap. Flow %
-82.34%
Top 10 Hldgs %
70.94%
Holding
41
New
11
Increased
5
Reduced
13
Closed
10

Top Buys

Rank Stock Value
1
BLU
BELLUS Health Inc.
BLU
+$5.54M
2
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$3.82M
3
CRSP icon
CRISPR Therapeutics
CRSP
+$2.63M
4
AXSM icon
Axsome Therapeutics
AXSM
+$2.18M
5
KPTI icon
Karyopharm Therapeutics
KPTI
+$2.15M

Top Sells

Rank Stock Value
1
IOVA icon
Iovance Biotherapeutics
IOVA
+$37.6M
2
ADVM
Adverum Biotechnologies
ADVM
+$14.1M
3
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$11.2M
4
VCYT icon
Veracyte
VCYT
+$9.82M
5
ATNX
Athenex, Inc. Common Stock
ATNX
+$9.36M

Sector Composition

Rank Sector Weight
1 Healthcare 91.74%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PTCT icon
26
PTC Therapeutics
PTCT
$5.68B
$1.22M 0.88%
+36,000
New +$1.57M
FOLD
27
DELISTED
Amicus Therapeutics
FOLD
$1.12M 0.81%
140,000
-210,000
-60% -$2.28M
APLT
28
DELISTED
Applied Therapeutics
APLT
$912K 0.66%
+83,000
New +$783K
KALV
29
DELISTED
KalVista Pharmaceuticals
KALV
$290K 0.21%
25,000
-188,000
-88% -$3.04M
VIRX
30
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$288K 0.21%
+11,429
New +$330K
CEMI
31
DELISTED
Chembio diagnostics, Inc.
CEMI
$255K 0.18%
41,667
– –
ADVM
32
DELISTED
Adverum Biotechnologies
ADVM
– –
-119,000
Closed -$14.1M
DHR icon
33
Danaher
DHR
$139B
– –
-12,972
Closed -$1.64M
CMRX
34
DELISTED
Chimerix, Inc.
CMRX
– –
-280,000
Closed -$1.21M
VRAY
35
DELISTED
ViewRay, Inc.
VRAY
– –
-842,500
Closed -$7.42M
ATNX
36
DELISTED
Athenex, Inc. Common Stock
ATNX
– –
-23,625
Closed -$9.36M
DRNA
37
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
– –
-384,500
Closed -$6.06M
IMMU
38
DELISTED
Immunomedics Inc
IMMU
– –
-225,000
Closed -$3.12M
BHVN
39
CALL
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
– –
-50,000
Closed -$2.19M
BHVN
40
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
– –
-255,000
Closed -$11.2M
BHVN
41
PUT
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
– –
-50,000
Closed -$2.19M
1
2

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
KCAM
Kagan Cocozza Asset Management Mickleton, New Jersey $142M AUM 12.02% 1-Year Est. Return

Acuta Capital Partners's Q3 2019 Portfolio in Review

As of Q3 2019, Acuta Capital Partners held 41 positions worth $139M, down 51% from $281M the previous quarter. Its ten largest holdings account for 71% of the portfolio.

Acuta Capital Partners withdrew a net $114M in Q3 2019, closing 10 positions and reducing 13 holdings. Its most notable exit was Adverum Biotechnologies, an estimated $14.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 86% a quarter earlier.

Against the trend, Acuta Capital Partners opened a new position in BELLUS Health Inc. worth $5.02M.

  • Acuta Capital Partners's largest Q3 2019 buy was BELLUS Health Inc.: 785,000 shares worth $5.02M.
  • Acuta Capital Partners added most to CRISPR Therapeutics in Q3 2019, an estimated $2.63M increase.
  • Acuta Capital Partners's biggest Q3 2019 reduction was Iovance Biotherapeutics, cutting an estimated $37.6M.
  • Acuta Capital Partners fully exited Adverum Biotechnologies in Q3 2019, selling an estimated $14.1M.
  • Acuta Capital Partners's ten largest holdings make up 71% of its $139M portfolio in Q3 2019.
  • Acuta Capital Partners opened 11 new positions and closed 10 in Q3 2019.
  • Acuta Capital Partners's portfolio value fell 51% quarter-over-quarter to $139M.

Based on Acuta Capital Partners's 13F filing for Q3 2019, filed 14 Nov 2019.